Head and Neck Squamous Cell Carcinoma Epidemiology Forecast - 2036

Head and Neck Squamous Cell Carcinoma (HNSCC) Insights and Trends

• The rising incidence of HNSCC is strongly associated with Human Papillomavirus (HPV) infection, with more than 90% of oropharyngeal cancer cases attributed to HPV in the US. Among these, the HPV16 subtype is responsible for around 90% of the cases. There is an opportunity to enhance current HNSCC treatments by developing immunotherapeutic approaches specifically designed to target HPV biology.
• Several European countries, including Spain, Italy, and the UK, have historically shown a lower burden of HPV-positive oropharyngeal cancer (OPC). However, in recent years, there has been a notable rise in both OPC incidence and the prevalence of HPV-driven OPC, suggesting a shifting disease landscape and highlighting the growing impact of HPV in regions previously considered low-burden.
• In 2025, the total incident cases of HPV16+ HNSCC were 47,711 in the 7MM. These cases are projected to reach up to 60,000 by 2036. The overall increase in HNC incidence is primarily driven by the rising burden of HPV-positive Oropharyngeal Squamous Cell Carcinoma (OPSCC), persistent tobacco use, lifestyle risk factors, and an aging population. Additionally, increasing awareness and improved diagnostic capabilities are contributing to higher detection rates and underscoring the need for tailored prevention and treatment strategies.
• Among the total site-specific cases of HNSCC in the US, oropharynx cases represented 31.1% while salivary gland cases were the lowest at 1.8%.
• In 2025, Among stage-specific cases of HPV16+ OPSCC, regional stages (III-IVB) account for over 70% in the United States .
• HPV16 is a major cause of HNSCC, a severe, life-threatening condition typically diagnosed in middle-aged adults. Advanced-stage cancers often have a very short median survival.
• Several ctDNA and biomarkers, including p16, E6/E7 oncoproteins, and noncoding RNAs (microRNAs, long noncoding RNAs), aid in diagnosing, prognosticating, and managing HPV-related cancers. Techniques like ddPCR, NGS, and CRISPR-based diagnostics show high sensitivity and specificity.
• Up to 10%-25% of patients with early-stage HPV16+ tumors are likely to relapse within two years.
• The risk of locoregional or distant recurrence is considerably lower in HPV-positive patients than in HPV-negative ones, regardless of the treatment method (surgical or non-surgical).

Head and Neck Squamous Cell Carcinoma (HNSCC) Epidemiology Forecast in the United States

• 2025 Incident Cases of HNSCC: ~65,022
• HNSCC Growth Rate (2026-2036): 1.97% CAGR

DelveInsight's 'Head and Neck Squamous Cell Carcinoma (HNSCC) - Epidemiology Forecast - 2036' report delivers an in-depth understanding of the HNSCC, historical and forecasted epidemiology in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Head and Neck Squamous Cell Carcinoma (HNSCC) Understanding and Diagnosis Algorithm

Head and Neck Squamous Cell Carcinoma (HNSCC) Overview

HNSCC comprises a group of malignancies originating from the squamous cells lining the head and neck region, including the oral cavity, hypopharynx, nasopharynx, oropharynx, lip, nasal cavity, paranasal sinuses, and salivary glands. These structures play essential roles in respiration, swallowing, and conditioning inspired air by filtering and humidifying it. HNSCC represents a significant global health burden, with incidence and mortality rates showing considerable variation across geographic regions and demographic groups. The disease is more prevalent in certain populations, particularly men, older adults, and individuals of lower socioeconomic status.

Head and Neck Squamous Cell Carcinoma (HNSCC) Diagnosis

Diagnosis of HNSCC is confirmed by biopsy of the primary tumor or neck mass, with the approach depending on lesion location, primary tumors are usually sampled with cup forceps, incisional, or excisional biopsy, while suspicious cervical lymph nodes undergo fine-needle aspiration (FNA); excisional neck mass biopsy is avoided unless FNA is repeatedly non-diagnostic, no primary is found, or lymphoma is suspected. Histopathology shows varying degrees of squamous differentiation, from well-differentiated tumors with keratin pearls to poorly differentiated tumors with pleomorphism and minimal keratinization; HPV-negative cases are often well or moderately differentiated, whereas HPV-positive tumors tend to be poorly differentiated or basaloid. Diagnosis is typically made with hematoxylin and eosin staining, with immunohistochemistry for pancytokeratin, cytokeratin 5/6, and p63 used for poorly differentiated cases. HPV testing is mandatory for all oropharyngeal and unknown primary tumors, with p16^INK4A^ immunohistochemistry (positive if >70% diffuse staining) serving as the standard surrogate marker for HPV status.

Head and Neck Squamous Cell Carcinoma (HNSCC) Epidemiology

Key Findings from Head and Neck Squamous Cell Carcinoma (HNSCC) Epidemiological Analysis and Forecast

• According to DelveInsight's estimates, the total incident cases of HNSCC in the 7MM were approximately 153,500 in 2025.
• It has been observed that among EU4 and the UK, site-specific cases of HNSCC were found maximum in the oral cavity in 2025.
• Germany accounted for about 2,700 OPSCC incident cases in 2025.
• Japan accounted for about 30,000 cases of HPV16+ OPSCC incident cases in 2025.

Scope of the Report:

The report covers a segment of an executive summary, a descriptive overview of HNSCC, explaining its causes, signs and symptoms, and pathogenesis.

• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression.

Report Insights

HNSCC Patient Population Forecast

Report Key Strengths

• Epidemiology-based (epi-based) Bottom-up Forecasting
• 11-year Forecast
• Patient Burden Trends (by Geography)

FAQs:

• What are the disease risks, burdens, and unmet needs of HNSCC? What will be the growth opportunities across the 7MM concerning the patient population with HNSCC?
• What is the historical and forecasted HNSCC patient pool in the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?

Reasons to Buy:

• Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• To understand key opinion leaders' perspectives around the diagnostic challenges to overcome barriers in the future.
• Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.